Navigation Links
Potential drug molecule shows enhanced anti-HIV activity
Date:8/9/2012

Researchers from Munich and Naples have shown that minimal modification of a synthetic peptide with anti-HIV activity results in a new compound with more than two orders of magnitude higher binding affinity to the chemokine receptor CXCR4 and greatly improved anti-HIV activity. This could be a step toward the design of new, more effective drugs against AIDS, inflammatory diseases, and some forms of cancer.

Different strains of HIV-1 use either the chemokine receptor CCR5 or CXCR4 for entry into immune cells. While drugs that block usage of CCR5 by the virus are already available for anti-HIV therapy, no drugs have been approved that prevent the virus from using the CXCR4 receptor. Because the new cyclic peptide may be used to block CXCR4, it is a promising new drug candidate to block HIV-1 infections.

An international, interdisciplinary team including researchers in pharmaceutical radiochemistry and chemistry at the Technische Universitt Mnchen (TUM), a group of molecular modelers at the University of Naples, and virologists at the Helmholtz Zentrum Mnchen reported the results in Angewandte Chemie International Edition. This work was initiated by the radiochemists and organic chemists at TUM, who realized that their approach to modifying peptides as high-affinity CXCR4 ligands for imaging of cancers also has the potential to open a whole new area of drug research.

The researchers used a smart trick to augment both the binding affinity and the anti-HIV activity of an already known lead structure: They shifted one of the important side chains from the carbon to a neighboring nitrogen, thus fixing the skeleton of the molecule to present its binding groups in an improved orientation.

The cyclic structure of the peptide, with one unnatural D-amino acid (the mirror image of the natural amino acid tyrosine) and one so-called "peptoid" structure, makes the compound stable against enzymatic degradation and thus suitable for in vivo applications. Since CXCR4 receptors also play an important role in cancer metastasis, derivatives of this compound are also being tested as new agents for imaging and treatment of cancer. The team's "frozen peptoid" displays a 400 to 1500 times higher binding affinity to the CXCR4 ligand compared to other CXCR4-targeting compounds currently under clinical development, including one already involved in the treatment of non-Hodgkin lymphoma and multiple myeloma.

"We are very happy that the specific modifications designed by our team have led to a drug compound that may be useful for treatment of multiple life-threatening diseases," says Prof. Horst Kessler, a senior fellow of the TUM Institute for Advanced Study and "emeritus of excellence" in the TUM Department of Chemistry. "For anti-HIV therapy," adds Prof. Ruth Brack-Werner, a virologist from the Helmholtz Zentrum, "the new compound may provide a drug against particularly aggressive HIV-1 strains that come up in HIV-infected individuals after many years of infection." "We look forward with great enthusiasm to the next preclinical and clinical tests," says Prof. Hans-Jrgen Wester, TUM Chair of Pharmaceutical Radiochemistry. "These compounds offer exciting possibilities."


'/>"/>

Contact: Patrick Regan
regan@zv.tum.de
49-089-289-10515
Technische Universitaet Muenchen
Source:Eurekalert  

Related biology news :

1. Epigenetic signatures direct the repair potential of reprogrammed cells
2. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
3. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
4. Researchers report potential for a moderate New England red tide in 2012
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Researchers find potential dark side to diets high in beta-carotene
7. Beehive extract shows potential as prostate cancer treatment
8. Gene therapy for hearing loss: Potential and limitations
9. Folic acid food enrichment potentially protective against childhood cancers
10. Nuisance seaweed found to produce compounds with biomedical potential
11. Potential new approach to regenerating skeletal muscle tissue
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential drug molecule shows enhanced anti-HIV activity
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: